Literature DB >> 11900879

The Li-Fraumeni syndrome.

Agnès Chompret1.   

Abstract

Li-Fraumeni syndrome (LFS) has been the most common terminology used for the syndrome. It is a rare familial dominantly inherited cancer syndrome characterized by a wide spectrum of neoplasms occurring in children and young adults. The canonical definition of LFS includes a proband diagnosed with sarcoma before 45 years of age, a first-degree relative with cancer before this same age and another first- or second-degree relative in the lineage with any cancer before this age or sarcoma at any age. Multiple studies have reported p53 germline mutations in LFS families in various parts of the world. As in sporadic tumors, loss of heterozygosity leading to the inactivation of the wild-type allele by deletion or mutation is observed in LFS tumors. Cancer-risk in mutation carriers has been estimated to be 73% in males and nearly 100% in females, the difference almost entirely explained by breast cancer. The identification of germline p53 mutations in rare cancer-prone families has given rise to the medical, counseling, psychological and ethical problems.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11900879     DOI: 10.1016/s0300-9084(01)01361-x

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  15 in total

1.  Familial gastric cancer: update for practice management.

Authors:  Giovanni Corso; Daniele Marrelli; Franco Roviello
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

2.  Familial gastric cancers with Li-Fraumeni Syndrome: a case repast.

Authors:  Il-Jin Kim; Hio-Chung Kang; Yong Shin; Byong-Chul Yoo; Han-Kwang Yang; Jae-Gahb Park
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Increased predisposition to cancer in brothers and offspring of testicular tumor patients.

Authors:  Sarolta Gundy; Mária Babosa; Márta Baki; István Bodrogi
Journal:  Pathol Oncol Res       Date:  2004-12-27       Impact factor: 3.201

4.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.

Authors:  G Bougeard; S Baert-Desurmont; I Tournier; S Vasseur; C Martin; L Brugieres; A Chompret; B Bressac-de Paillerets; D Stoppa-Lyonnet; C Bonaiti-Pellie; T Frebourg
Journal:  J Med Genet       Date:  2005-10-28       Impact factor: 6.318

5.  Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures.

Authors:  Charlotte Sagne; Virginie Marcel; Maria Bota; Ghyslaine Martel-Planche; Amanda Nobrega; Edenir Inêz Palmero; Laury Perriaud; Mathieu Boniol; Stephan Vagner; David G Cox; Chang S Chan; Jean-Louis Mergny; Magali Olivier; Patricia Ashton-Prolla; Janet Hall; Pierre Hainaut; Maria Isabel Achatz
Journal:  Carcinogenesis       Date:  2013-12-11       Impact factor: 4.944

Review 6.  Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention.

Authors:  María Sereno; Cristina Aguayo; Carmen Guillén Ponce; César Gómez-Raposo; Francisco Zambrana; Miriam Gómez-López; Enrique Casado
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

7.  Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome.

Authors:  June A Peters; Regina Kenen; Renee Bremer; Shannon Givens; Sharon A Savage; Phuong L Mai
Journal:  J Genet Couns       Date:  2015-11-30       Impact factor: 2.537

Review 8.  Familial Gastric Cancers.

Authors:  Namrata Setia; Jeffrey W Clark; Dan G Duda; Theodore S Hong; Eunice L Kwak; John T Mullen; Gregory Y Lauwers
Journal:  Oncologist       Date:  2015-09-30

9.  Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo.

Authors:  H Caldas; M P Holloway; B M Hall; S J Qualman; R A Altura
Journal:  J Med Genet       Date:  2005-05-20       Impact factor: 6.318

10.  CREG1 enhances p16(INK4a) -induced cellular senescence.

Authors:  Benchamart Moolmuang; Michael A Tainsky
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.